Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1938]

MURANO trial: Venetoclax-rituximab shows sustained benefit in relapsed...

Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia

$MURANO trial: Venetoclax-rituximab shows sustained benefit in relapsed/refractory chronic lymphocytic leukaemia ( Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia )$

Glasdegib in combination with azacitidine in patients with untreated higher...

Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA

Glasdegib in combination with azacitidine in patients with untreated higher-risk myelodysplastic syndromes and AML ( Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA )

Addressing the treatment gap for patients with relapsed/refractory primary...

Prof Evangelos Terpos and Prof Efstathios Kastritis

$Addressing the treatment gap for patients with relapsed/refractory primary systemic AL amyloidosis: TOURMALINE-AL1 trial results ( Prof Evangelos Terpos and Prof Efstathios Kastritis )$

Carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

Carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

Challenges and importance of long-term treatment for newly diagnosed multiple...

Prof Sagar Lonial, Prof Meral Beksaç, Dr Robert Rifkin

Challenges and importance of long-term treatment for newly diagnosed multiple myeloma patients; community-based trial data ( Prof Sagar Lonial, Prof Meral Beksaç, Dr Robert Rifkin )

Novel multi-antigen targeted CAR-NK cell for the treatment of B cell...

Dr Bahram Valamehr - Fate Therapeutics Inc., San Diego, USA

Novel multi-antigen targeted CAR-NK cell for the treatment of B cell malignancies ( Dr Bahram Valamehr - Fate Therapeutics Inc., San Diego, USA )

Multiple myeloma: Anti-BCMA BiTE AMG 701 shows preclinical promise

Dr Yu-Tzu Tai - Dana-Farber Cancer Institute, Boston, USA

Multiple myeloma: Anti-BCMA BiTE AMG 701 shows preclinical promise ( Dr Yu-Tzu Tai - Dana-Farber Cancer Institute, Boston, USA )

Evaluating emerging mutations in patients with acute myeloid leukaemia who...

Dr Catherine Smith - University of California San Francisco, San Francisco, USA

Evaluating emerging mutations in patients with acute myeloid leukaemia who relapsed while receiving gilteritinib therapy in the ADMIRAL trial ( Dr Catherine Smith - University of California San Francisco, San Francisco, USA )

Maintenance decitabine after intensive therapy for AML in older FLT3-ITD...

Dr James Foran - Mayo Clinic Florida, Jacksonville, USA

Maintenance decitabine after intensive therapy for AML in older FLT3-ITD-negative patients ( Dr James Foran - Mayo Clinic Florida, Jacksonville, USA )

Bispecific CAR T-cell therapy as treatment for hard to treat multiple myeloma

Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China

Bispecific CAR T-cell therapy as treatment for hard to treat multiple myeloma ( Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China )

Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin...

Prof Stephen Schuster - University of Pennsylvania, Philadelphia, USA

Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients ( Prof Stephen Schuster - University of Pennsylvania, Philadelphia, USA )

CAR T-cell therapy in hard-to-treat multiple myeloma produces sustained...

Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China

CAR T-cell therapy in hard-to-treat multiple myeloma produces sustained remissions ( Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China )

More from ecancer